NCI Introduces Personalized Survival Calculator for Peritoneal MesotheliomaResearch & Clinical Trials
Asbestos.com is the nation’s most trusted mesothelioma resource
The Mesothelioma Center at Asbestos.com has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.
Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.
More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.
About The Mesothelioma Center at Asbestos.com
- Assisting mesothelioma patients and their loved ones since 2006.
- Helps more than 50% of mesothelioma patients diagnosed annually in the U.S.
- A+ rating from the Better Business Bureau.
- 5-star reviewed mesothelioma and support organization.
"My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family."LashawnMesothelioma patient’s daughter
How to Cite Asbestos.com’s Article
Franz, F. (2020, October 16). NCI Introduces Personalized Survival Calculator for Peritoneal Mesothelioma. Asbestos.com. Retrieved October 6, 2022, from https://www.asbestos.com/news/2012/12/26/nci-researchers-introduce-new-personalized-survival-calculator-for-peritoneal-mesothelioma/
Franz, Faith. "NCI Introduces Personalized Survival Calculator for Peritoneal Mesothelioma." Asbestos.com, 16 Oct 2020, https://www.asbestos.com/news/2012/12/26/nci-researchers-introduce-new-personalized-survival-calculator-for-peritoneal-mesothelioma/.
Franz, Faith. "NCI Introduces Personalized Survival Calculator for Peritoneal Mesothelioma." Asbestos.com. Last modified October 16, 2020. https://www.asbestos.com/news/2012/12/26/nci-researchers-introduce-new-personalized-survival-calculator-for-peritoneal-mesothelioma/.
Before consenting to an aggressive, high-risk treatment regimen, cancer patients want to know if the therapies have the potential to improve their prognosis.
For many cancers — including peritoneal mesothelioma — oncologists rely on a set of personal and tumor-related factors to identify ideal candidates for curative treatment. However, the evaluation rarely predicts the impact the treatment will have on patient survival.
Most sources report a median peritoneal mesothelioma survival of six to 12 months. But patients like 10-year survivor Michelle Marshall and 12-year survivor Tammy Frank underwent extensive treatment programs that helped them defy the odds.
Marshall has completed a dozen rounds of chemotherapy, while Frank takes 12 medications a day to maintain the results of an elaborate multimodal regimen.
Some patients who are diagnosed with extensive cancer are less likely to improve their prognosis with curative therapies. These patients may have a better quality of life with a gentler palliative approach.
To create a more personalized prognostic scale — and in turn rule out surgical interventions that are unlikely to extend the patient’s life expectancy — researchers at the National Cancer Institute developed a novel program that can more accurately predict survival before surgery.
A Personalized Peritoneal Mesothelioma Nomogram
This specific calculation program, known in the scientific world as a nomogram, generates two statistics: three-year overall survival and five-year overall survival.
Researchers took 25 variables into consideration. These ranged from demographic factors (such as age and sex) to differences in laboratory testing to factors that were unique for each patient’s operation.
By the end of the study, the researchers identified three characteristics that produced the greatest impact on overall survival:
- The cancer’s cellular subtype
- The concentration of the CA-125 antigens in the patient’s blood
- Whether or not the patient received radiation before their operation
The nomogram assigns the heaviest weight to these factors. However, it also considers the patient’s score on the peritoneal carcinomatosis index.
For this index, doctors evaluate 12 distinct abdominal sections for the presence and size of cancerous growths. Patients receive a score on a scale of 0 to 39, with higher scores representing more extensive cancer. Patients studied for the development of the nomogram had a mean index score of 15.
The final model weighs each of these factors, then generates a color-coded survival chart that helps doctors quickly identify patient-specific pre-surgical survival rates.
Influence on Treatment
Each of the patients in the developmental study underwent the standard treatment regimen for malignant peritoneal mesothelioma: a cisplatin-based hyperthermic intraperitoneal chemotherapy regimen, followed by cytoreductive surgery (CRS).
In the 104-patient study, the three-year and five-year survival rates were 58 percent and 46 percent, respectively. Approximately 66 percent of the patients received a post-cytoreduction score of 0 or 1 (indicating that surgery removed all visible tumor nodules under 2.5 mm in size).
Researchers hope that the model can help patients know just how helpful surgery could be in their journey to cancer remission.
“Personalized survival times can potentially guide treatment and surveillance,” the team explained in Annals of Surgical Oncology.
“Pre-CRS estimation of survival times — might prevent CRS in patients unlikely to achieve favorable outcomes despite surgical intervention.”
These individualized estimates can help patients and doctors make more informed decisions on whether surgery will benefit their treatment goals.